CoChat

Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial

Open access
Ueki, Kohjiro, Sasako, Takayoshi, Okazaki, Yukiko, Kato, Masayuki, Okahata, Sumie, Katsuyama, Hisayuki, Haraguchi, Mikiko, Morita, Ai, Ohashi, Ken, Hara, Kazuo, Morise, Atsushi, Izumi, Kazuo, Ishizuka, Naoki, Ohashi, Yasuo, Noda, Mitsuhiko, Kadowaki, Takashi, Haneda, Masakazu, Iwashima, Yasunori, Suda, Toshihiro, Tamasawa, Naoki, Daimon, Makoto, Satoh, Jo, Takebe, Noriko, Ishigaki, Yasushi, Watanabe, Tsuyoshi, Satoh, Hiroaki, Kasai, Kikuo, Aso, Yoshimasa, Ishibashi, Shun, Katayama, Shigehiro, Ishikawa, San-e, Kakei, Masafumi, Namai, Kazuyuki, Hashimoto, Naotake, Suzuki, Yoshifumi, Onishi, Shunichiro, Yokote, Koutaro, Matsuda, Masafumi, Masuzawa, Masahiro, Hayashi, Yoichi, Saito, Satoshi, Ogihara, Norikazu, Ishihara, Hisamitsu, Tajima, Naoko, Utsunomiya, Kazunori, Shimada, Akira, Itoh, Hiroshi, Kawamori, Ryuzo, Watada, Hirotaka, Hayashi, Michio, Mori, Yasumichi, Shiba, Teruo, Isogawa, Akihiro, Sakura, Hiroshi, Odawara, Masato, Tobe, Kazuyuki, Tsukamoto, Kazuhisa, Yamauchi, Toshimasa, Teramoto, Tamio, Hirata, Yukio, Uchimura, Isao, Ogawa, Yoshihiro, Yoshino, Gen, Hirose, Takahisa, Kajio, Hiroshi, Atsumi, Yoshihito, Shimada, Akira, Oikawa, Yoichi, Araki, Atsushi, Ueki, Akio, Ohno, Atsushi, Kitaoka, Masafumi, Fujita, Yoshikuni, Moriya, Tatsumi, Tojo, Taiki, Shichiri, Masayoshi, Suzuki, Daisuke, Toyoda, Masao, Hamano, Kumiko, Komi, Rieko, Terauchi, Yasuo, Kuzuya, Nobuaki, Yamada, Masayo, Takamura, Toshinari, Imura, Mitsuo, Tanaka, Hiroshi, Hayashi, Masayuki, Kato, Yasuhisa, Itoh, Mitsuyasu, Suzuki, Atsushi, Nakayama, Mikihiro, Sano, Takahisa, Nakashima, Eitaro, Sumida, Yasuhiro, Yano, Yutaka, Tanaka, Tsuyoshi, Murata, Kazuya, Kashiwagi, Atsunori, Maegawa, Hiroshi, Kono, Shigeo, Inagaki, Nobuya, Kosugi, Keisuke, Yasuda, Tetsuyuki, Yoshimasa, Yasunao, Kishimoto, Ichiro, Sato, Toshihiko, Hosoi, Masayuki, Yamasaki, Tomoyuki, Matsuhisa, Munehide, Shimomura, Iichiro, Taniguchi, Ataru, Kuroe, Akira, Kurose, Takeshi, Ohara, Takeshi, Sakaguchi, Kazuhiko, Namba, Mitsuyoshi, Kaku, Kohei, Fujiwara, Masazumi, Shimizu, Ikki, Ono, Keizo, Ebisui, Osamu, Tanizawa, Yukio, Okada, Yosuke, Natori, Shoichi, Kodera, Takehiko, Sato, Naoichi, Ide, Makoto, Yamada, Kentaro, Umeda, Fumio, Natori, Shoichi, Eto, Tomoaki, Mimura, Kazuo, Hiramatsu, Shinsuke, Inoue, Tomoaki, Takei, Ryoko, Ogo, Atsushi, Eguchi, Katsumi, Kawasaki, Eiji, Koide, Yuji, Araki, Eiichi, Jinnouchi, Hideaki, Yamamoto, Hiroaki, Motoyoshi, Mitsutaka, Hiyoshi, Toru, Tanaka, Yasushi, Momoki, Tadahisa, Sato, Koichiro, Yoneyama, Akihiko, Ito, Kenichi, Sobajima, Hiroshi, Ikegami, Hiroshi, Ikeda, Masaki, Ikeda, Hiroki, Takahashi, Kenji, Makino, Hirofumi, Ueda, Yasuo, Nakazato, Masamitsu · 2017 · The Lancet Diabetes & Endocrinology

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

Background Limited evidence suggests that multifactorial interventions for control of glucose, blood pressure, and lipids reduce macrovascular complications and mortality in patients with type 2 diabetes. However, safe and effective treatment targets for these risk factors have not been determined for such interventions.Methods In this multicentre, open-label, randomised, parallel-group trial, undertaken at 81 clinical sites in Japan, we randomly assigned (1:1) patients with type 2 diabetes aged 45-69 years with hypertension, dyslipidaemia, or both, and an HbA 1c of 6·9% (52·0 mmol/mol) or higher, to receive conventional therapy for glucose, blood pressure, and lipid control (targets: HbA 1c <6·9% [52·0 mmol/mol], blood pressure <130/80 mm Hg, LDL cholesterol <120 mg/dL [or 100 mg/dL in patients with a history of coronary artery disease]) or intensive therapy (HbA 1c <6·2% [44·3 mmol/mol], blood pressure <120/75 mm Hg, LDL cholesterol <80 mg/dL [or 70 mg/dL in patients with a history of coronary artery disease]). Randomisation was done using a computer-generated, dynamic balancing method, stratified by sex, age, HbA 1c, and history of cardiovascular disease. Neither patients nor investigators were masked to group assignment. The primary outcome was occurrence of any of a composite of myocardial infarction, stroke, revascularisation (coronary artery bypass surgery, percutaneous transluminal coronary angioplasty, carotid endarterectomy, percutaneous transluminal cerebral angioplasty, and carotid artery stenting), and all-cause mortality. The primary analysis was done in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00300976.Findings Between June 16, 2006, and March 31, 2009, 2542 eligible patients were randomly assigned to intensive therapy or conventional therapy (1271 in each group) and followed up for a median of 8·5 years (IQR 7·3-9·0). Two patients in the intensive therapy group were found to be ineligible after randomisation and were excluded from the analyses. During the intervention period, mean HbA 1c, systolic blood pressure, diastolic blood pressure, and LDL cholesterol concentrations were significantly lower in the intensive therapy group than in the conventional therapy group (6·8% [51·0 mmol/mol] vs 7·2% [55·2 mmol/mol]; 123 mm Hg vs 129 mm Hg; 71 mm Hg vs 74 mm Hg; and 85 mg/dL vs 104 mg/dL, respectively; all p<0·0001). The primary outcome occurred in 109 patients in the intensive therapy group and in 133 patients in the conventional therapy group (hazard ratio [HR] 0·81, 95% CI 0·63-1·04; p=0·094). In a post-hoc breakdown of the composite outcome, frequencies of all-cause mortality (HR 1·01, 95% CI 0·68-1·51; p=0·95) and coronary events (myocardial infarction, coronary artery bypass surgery, and percutaneous transluminal coronary angioplasty; HR 0·86, 0·58-1·27; p=0·44) did not differ between groups, but cerebrovascular events (stroke, carotid endarterectomy, percutaneous transluminal cerebral angioplasty, and carotid artery stenting) were significantly less frequent in the intensive therapy group (HR 0·42, 0·24-0·74; p=0·002). Apart from non-severe hypoglycaemia (521 [41%] patients in the intensive therapy group vs 283 [22%] in the conventional therapy group, p<0·0001) and oedema (193 [15%] vs 129 [10%], p=0·0001), the frequencies of major adverse events did not differ between groups.Interpretation Our results do not fully support the efficacy of further intensified multifactorial intervention compared with current standard care for the prevention of a composite of coronary events, cerebrovascular events, and all-cause mortality. Nevertheless, our findings suggest a potential benefit of an intensified intervention for the prevention of cerebrovascular events in patients with type 2 diabetes.Funding Ministry of Health, Labour and Welfare of Japan, Asahi Kasei Pharma, Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Kissei Pharmaceutical, Kowa Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Novo Nordisk, Ono Pharmaceutical, Pfizer, Sanwa Kagaku Kenkyusho, Shionogi, Sumitomo Dainippon Pharma, Taisho Toyama Pharmaceutical, and Takeda.

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(17)30327-3

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

12 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 39 references

Cited by

See all 321

Metadata

Authors
Ueki, K., Sasako, T., Okazaki, Y., Kato, M., Okahata, S., Katsuyama, H., Haraguchi, M., Morita, A., Ohashi, K., Hara, K., Morise, A., Izumi, K., Ishizuka, N., Ohashi, Y., Noda, M., Kadowaki, T., Haneda, M., Iwashima, Y., Suda, T., Tamasawa, N., Daimon, M., Satoh, J., Takebe, N., Ishigaki, Y., Watanabe, T., Satoh, H., Kasai, K., Aso, Y., Ishibashi, S., Katayama, S., Ishikawa, S.-E., Kakei, M., Namai, K., Hashimoto, N., Suzuki, Y., Onishi, S., Yokote, K., Matsuda, M., Masuzawa, M., Hayashi, Y., Saito, S., Ogihara, N., Ishihara, H., Tajima, N., Utsunomiya, K., Shimada, A., Itoh, H., Kawamori, R., Watada, H., Hayashi, M., Mori, Y., Shiba, T., Isogawa, A., Sakura, H., Odawara, M., Tobe, K., Tsukamoto, K., Yamauchi, T., Teramoto, T., Hirata, Y., Uchimura, I., Ogawa, Y., Yoshino, G., Hirose, T., Kajio, H., Atsumi, Y., Shimada, A., Oikawa, Y., Araki, A., Ueki, A., Ohno, A., Kitaoka, M., Fujita, Y., Moriya, T., Tojo, T., Shichiri, M., Suzuki, D., Toyoda, M., Hamano, K., Komi, R., Terauchi, Y., Kuzuya, N., Yamada, M., Takamura, T., Imura, M., Tanaka, H., Hayashi, M., Kato, Y., Itoh, M., Suzuki, A., Nakayama, M., Sano, T., Nakashima, E., Sumida, Y., Yano, Y., Tanaka, T., Murata, K., Kashiwagi, A., Maegawa, H., Kono, S., Inagaki, N., Kosugi, K., Yasuda, T., Yoshimasa, Y., Kishimoto, I., Sato, T., Hosoi, M., Yamasaki, T., Matsuhisa, M., Shimomura, I., Taniguchi, A., Kuroe, A., Kurose, T., Ohara, T., Sakaguchi, K., Namba, M., Kaku, K., Fujiwara, M., Shimizu, I., Ono, K., Ebisui, O., Tanizawa, Y., Okada, Y., Natori, S., Kodera, T., Sato, N., Ide, M., Yamada, K., Umeda, F., Natori, S., Eto, T., Mimura, K., Hiramatsu, S., Inoue, T., Takei, R., Ogo, A., Eguchi, K., Kawasaki, E., Koide, Y., Araki, E., Jinnouchi, H., Yamamoto, H., Motoyoshi, M., Hiyoshi, T., Tanaka, Y., Momoki, T., Sato, K., Yoneyama, A., Ito, K., Sobajima, H., Ikegami, H., Ikeda, M., Ikeda, H., Takahashi, K., Makino, H., Ueda, Y., & Nakazato, M.
Affiliations
  • National Center for Global Health and Medicine (JP)
  • The University of Tokyo (JP)
  • Toranomon Hospital (JP)
  • Toho University Ohashi Medical Center (JP)
  • National Cancer Center Hospital (JP)
  • Jichi Medical University (JP)
  • Tokyo Takanawa Hospital (JP)
  • The Cancer Institute Hospital (JP)
  • Chuo University (JP)
  • Saitama Medical University (JP)
Corresponding author
Kadowaki, Takashi
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2017-12
Volume
5
Issue
12
Pages
951-964
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2767087620
Cited by
313
References
39
Citations by year
2026: 18 · 2025: 25 · 2024: 38 · 2023: 41 · 2022: 31 · 2021: 45 · 2020: 47 · 2019: 42 · 2018: 24 · 2017: 1
FWCI
24.62
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Diabetes & Endocrinology (acceptedVersion)
  • PubMed (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion)
Funders
  • Kissei
  • Bristol-Myers Squibb
  • Boehringer Ingelheim Japan
  • Eli Lilly and Company
  • Daiichi-Sankyo
  • Astellas Pharma US
  • Ministry of Health, Labour and Welfare
  • Japan Diabetes Foundation
  • Novartis Pharma
  • Ono Pharmaceutical
  • Novartis
  • Astellas Pharma
  • Meso Scale Diagnostics
  • Taisho Toyama Pharmaceutical Company
  • Boehringer Ingelheim
  • Mitsubishi Tanabe Pharma Corporation
  • Takeda Pharmaceutical Company
  • Kyowa Hakko Kirin
  • Bayer
  • Novo Nordisk
  • AstraZeneca
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, multifactorial intervention, tight glycemic control, HbA1c targets, blood pressure targets, LDL cholesterol targets, hypertension, dyslipidemia, cardiovascular events, myocardial infarction, stroke, revascularization, all-cause mortality, macrovascular complications, cardiovascular risk reduction, coronary artery disease, Japanese patients, middle-aged adults
MeSH terms
Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Humans, Japan, Male, Middle Aged, Mortality, Causality, Treatment Outcome, Early Medical Intervention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s2213-8587(17)30327-3
The paper
Ueki, K., Sasako, T., Okazaki, Y., Kato, M., Okahata, S., Katsuyama, H., Haraguchi, M., Morita, A., Ohashi, K., Hara, K., Morise, A., Izumi, K., Ishizuka, N., Ohashi, Y., Noda, M., Kadowaki, T., Haneda, M., Iwashima, Y., Suda, T., . . . Nakazato, M. (2017). Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(17)30327-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.